Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective.

@article{Orlewska2003CosteffectivenessAO,
  title={Cost-effectiveness analysis of enoxaparin versus unfractionated heparin in patients with acute coronary syndrome in Poland: modelling study from the hospital perspective.},
  author={Ewa Orlewska and Andrzej J. Budaj and Dariusz Tereszkowski-Kaminski},
  journal={PharmacoEconomics},
  year={2003},
  volume={21 10},
  pages={
          737-48
        }
}
UNLABELLED AIM AND PERSPECTIVE: To estimate the cost effectiveness of enoxaparin versus unfractionated heparin (UFH) in patients with acute coronary syndrome (ACS) from a Polish hospital perspective. This was intended to facilitate the decisionmaking process in selecting the most cost-effective treatment for ACS. METHOD A decision model was used to quantify costs and effectiveness of alternative treatments. Published results from the Efficacy and Safety of Subcutaneous Enoxaparin in Non-Q… CONTINUE READING